Letter

SSRIs and congenital defects

Author’s reply

BMJ 2009; 339 doi: 10.1136/bmj.b4295 (Published 21 October 2009)
Cite this as: BMJ 2009;339:b4295

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Christina Chambers, associate professor1
  1. 1Division of Dysmorphology and Teratology, Departments of Pediatrics and Family and Preventive Medicine, School of Medicine, University of California San Diego, 9500 Gilman Drive, MC 0828, La Jolla, CA 92093-0828, USA
  1. chchambers{at}ucsd.edu

    I did not intend my comments to be interpreted as minimising the risk.1 2 Rather, I intended to place the risks in context in terms of both size (which is estimated to be comparatively small compared with other known teratogens such as isotretinoin, which can affect more than 20% of exposed pregnancies) and the concomitant risks of no treatment or undertreatment.

    Healy mentions our California data …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular